Boxer Capital’s Ascendis Pharma A/S ASND Stock Holding History

Boxer Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-95,000	Closed	-$8.9M	–	55
2023 Q3	$8.9M	Hold	95,000	–	–	0.47%	45
2023 Q2	$8.48M	Hold	95,000	–	–	0.39%	50
2023 Q1	$10.2M	Hold	95,000	–	–	0.5%	44
2022 Q4	$11.6M	Buy	95,000 +25,000	+36%	+$2.9M	0.61%	41
2022 Q3	$7.23M	Hold	70,000	–	–	0.41%	44
2022 Q2	$6.51M	Buy	+70,000	New	+$6.6M	0.41%	46

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Boxer Capital's ASND Position: Q4 2023 in Review

Boxer Capital sold out of Ascendis Pharma A/S (ASND) in Q4 2023, closing a stake of 95,000 shares — an estimated $8.9M sold.

Boxer Capital first reported a position in ASND in Q2 2022 and held it in 6 quarters. The position peaked at $11.6M in Q4 2022. 185 funds tracked by Wall St. Rank hold ASND as of Q4 2023.

Boxer Capital reported no remaining Ascendis Pharma A/S position as of Q4 2023 after selling out during the quarter.
Boxer Capital sold 95,000 Ascendis Pharma A/S shares in Q4 2023, an estimated $8.9M.
Boxer Capital first reported a position in Ascendis Pharma A/S in Q2 2022 and held it in 6 quarters.
Boxer Capital's Ascendis Pharma A/S position peaked at $11.6M in Q4 2022.
185 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.